Liso-Cel Plus Ibrutinib Yields Deep Remissions in R/R CLL
Summary
Researchers evaluate outcomes with ibrutinib plus liso-cel CAR T-cell therapy in patients with heavily pretreated relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Description from Medscape.
Who is covering this
-
Liso-Cel Plus Ibrutinib Yields Deep Remissions in R/R CLL
Researchers evaluate outcomes with ibrutinib plus liso-cel CAR T-cell therapy in patients with heavily pretreated relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Comments
Comments need JavaScript.